Publisher: Bentham Science Publishers
E-ISSN: 1875-6212|16|3|254-268
ISSN: 1570-1611
Source: Current Vascular Pharmacology, Vol.16, Iss.3, 2018-03, pp. : 254-268
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Common therapies could improve outcome. Potent statins at high doses, such as atorvastatin and rosuvastatin,ameliorate NAFLD/NASH and reduce the mortality rates by half as compared with those onthe same statins but without liver disease and CVD-related events are reduced by atorvastatin for patientswith all stages of CKD. The new anti-diabetic medication classes, the sodium-glucose co-transporter-2 inhibitors (SGLT2i) andthe glucagon like peptide receptor agonists (GLP1 RA) for patients with NAFLD/NASH, CKD andT2DM are useful because they ameliorate NAFLD/NASH, delay the evolution of CKD, and substantiallyreduce CVD and all-cause mortality. Thus, the common use of high potency statins, renin-angiotensin-aldosterone system inhibitors, and thenewer anti-diabetic agents increase compliance and can substantially reduce CVD risk and the rate ofliver and kidney adverse events, improving quality of life and survival.
Related content
Vascular Disease and Risk Factors in Chronic Kidney Disease
Vascular Disease Prevention, Vol. 2, Iss. 4, 2005-10 ,pp. :